Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03226899 · ClinicalTrials.gov registry record · Phase 4
A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
A Phase 4 study, sponsored by Ironwood Pharmaceuticals.
- Terminated
- Registry status
- Phase 4
- Development phase
- 242
- Enrollment target
NCT03226899: Clinical Trial Phase 4 study, sponsored by Ironwood Pharmaceuticals.
NCT03226899 is a Phase 4 study that was terminated before completion, run by Ironwood Pharmaceuticals. The registered enrollment target is 242 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03226899, a Phase 4 study, was terminated before completion, sponsored by Ironwood Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 242 participants
- Enrollment target
Study Summary
This study evaluates the safety and efficacy of lesinurad administered with an XOI versus a placebo plus an XOI in gout participants who have moderate renal impairment and who are not at target level of serum urate (sUA).
Interventions
- DRUG Placebo
- DRUG Lesinurad
- DRUG corticosteroids
- DRUG colchicine
- DRUG XOI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2017-07-19 |
| Est. Completion | 2019-02-25 |
| Phase | Phase 4 |
Why NCT03226899 stopped before completion
NCT03226899 is an interventional study that assigns participants to a tested intervention. The registered 242 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03226899 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03226899 about?
NCT03226899 is a clinical study titled "A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment". This study evaluates the safety and efficacy of lesinurad administered with an XOI versus a placebo plus an XOI in gout participants who have moderate renal impairment and who are not at target level of serum urate (sUA).
What is the current status of trial NCT03226899?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 242 participants. The study started on 2017-07-19. Estimated completion is 2019-02-25.
What interventions are being tested in trial NCT03226899?
The interventions under investigation include: Placebo (DRUG), Lesinurad (DRUG), corticosteroids (DRUG), colchicine (DRUG), XOI (DRUG).
Who is sponsoring clinical trial NCT03226899?
This trial is sponsored by Ironwood Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03226899's enrollment target sits among peer trials
242 358th of 2000 higher than 1,641 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03556228 · 242 participants · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- NCT04260022 · 242 participants · Phase 1
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- NCT04459000 · 242 participants · NA
Substance Use Treatment and Access to Resources (STARS) Project
- NCT05644496 · 242 participants · Phase 4
ZYNRELEF for Pain Management in Total Knee Arthroplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI